0
Abstract: Poster Presentations |

IN COPD, NEBULIZED FORMOTEROL FUMARATE PROVIDES PROLONGED BRONCHODILATION AND INCREASED PATIENT SATISFACTION COMPARED TO ALBUTEROL/IPRATROPIUM MDI FREE TO VIEW

E. R. Sutherland, MD; Shari Brazinsky, MD; Gregory Feldman, MD; Joe McGinty, BS; Latanya Tomlinson, RN; Kimberly Denis-Mize, PhD*
Author and Funding Information

Dey, LP, Napa, CA


Chest


Chest. 2008;134(4_MeetingAbstracts):p107001. doi:10.1378/chest.134.4_MeetingAbstracts.p107001
Text Size: A A A
Published online

Abstract

PURPOSE:We conducted a randomized, open-label, crossover trial to evaluate bronchodilation and patient treatment satisfaction with twice-daily nebulized formoterol fumarate versus 4-times daily ipratropium/albuterol by metered-dose inhaler (MDI).

METHODS:After a 7-day screening period, subjects with COPD (n=109, 52.8% predicted FEV1) and no significant comorbidities were randomized to receive formoterol fumarate inhalation solution (FFIS 20 μg) twice-daily by nebulization or ipratropium bromide/albuterol sulfate combination by MDI (IPR/ALB 18/103 μg) 4-times daily for 2 weeks. Following a 1-week washout period, subjects crossed over to receive the other medication. Efficacy was assessed by spirometry at the start and end of each 2-week period, the transition dyspnea index, and a treatment satisfaction/preference survey.

RESULTS:At Day 14, mean morning pre-dose (trough) FEV1 was greater in the FFIS group (1.418 L) than the IPR/ALB group (1.319 L) (p<0.001). Peak FEV1and standardized FEV1 AUC0–6 were similar between groups. Both FFIS and IPR/ALB treatments provided clinically meaningful improvements in dyspnea scores. Treatment satisfaction and the perception of disease control were greater during FFIS treatment (p<0.05) than with IPR/ALB treatment.

CONCLUSION:Nebulized FFIS treatment provided bronchodilation comparable to IPR/ALB with significantly prolonged duration of action leading to improved morning pre-dose FEV1 in COPD subjects. Twice daily nebulized treatment also provided a perception of increased control over their lung disease, and increased treatment satisfaction compared to 4-times daily MDI combination therapy.

CLINICAL IMPLICATIONS:A twice-daily regimen of nebulized formoterol fumarate provides superior morning bronchodilation and increased patient preference versus 4-times-daily IPR/ALB in COPD treatment.

DISCLOSURE:Kimberly Denis-Mize, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, October 29, 2008

1:00 PM - 2:15 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543